Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Biomarkers Definitions Working Group.

Clin Pharmacol Ther. 2001 Mar;69(3):89-95. Review. No abstract available.

PMID:
11240971
2.

Surrogate and mediating endpoints: current status and future directions.

Prentice RL.

J Natl Cancer Inst. 2009 Feb 18;101(4):216-7. doi: 10.1093/jnci/djn515. Epub 2009 Feb 10. No abstract available.

PMID:
19211455
3.

The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.

Lonn E.

Pharmacoepidemiol Drug Saf. 2001 Oct-Nov;10(6):497-508. Review.

PMID:
11828831
4.
5.

Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design.

Lachenbruch PA, Rosenberg AS, Bonvini E, Cavaillé-Coll MW, Colvin RB.

Am J Transplant. 2004 Apr;4(4):451-7. Review.

6.

Surrogate markers and joint models for longitudinal and survival data.

Taylor JM, Wang Y.

Control Clin Trials. 2002 Dec;23(6):626-34.

PMID:
12505241
7.

Surrogate endpoints in randomized cardiovascular clinical trials.

Domanski M, Pocock S, Bernaud C, Borer J, Geller N, Revkin J, Zannad F.

Fundam Clin Pharmacol. 2011 Aug;25(4):411-3. doi: 10.1111/j.1472-8206.2010.00865.x. Epub 2010 Aug 4. Review.

PMID:
20698890
8.

Potential surrogate endpoints in cancer research--some considerations and examples.

Duffy SW, Treasure FP.

Pharm Stat. 2011 Jan-Feb;10(1):34-9. doi: 10.1002/pst.406.

PMID:
20029937
9.
10.

Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.

Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, Strand V, Conaghan PG, Ostergaard M, Maksymowych WP, Landewe R, Bresnihan B, Tak PP, Wakefield R, Mease P, Bingham CO 3rd, Hughes M, Altman D, Buyse M, Galbraith S, Wells G.

J Rheumatol. 2007 Mar;34(3):607-15.

PMID:
17343307
11.

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop.

De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL.

Control Clin Trials. 2001 Oct;22(5):485-502.

PMID:
11578783
12.

Design and endpoints of clinical trials in hepatocellular carcinoma.

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials.

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13. Review.

PMID:
18477802
13.

Design issues and outcomes in IBD clinical trials.

Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD, Sandborn WJ, Steinhart AH.

Inflamm Bowel Dis. 2005 Nov;11 Suppl 1:S22-8. Review.

PMID:
16254479
14.

Surrogate endpoints: the debate goes on.

Ellenberg SS.

Pharmacoepidemiol Drug Saf. 2001 Oct-Nov;10(6):493-6. No abstract available.

PMID:
11828830
15.

Biomarkers in Alzheimer's disease: not yet surrogate endpoints.

Coley N, Andrieu S, Delrieu J, Voisin T, Vellas B.

Ann N Y Acad Sci. 2009 Oct;1180:119-24. doi: 10.1111/j.1749-6632.2009.04947.x.

PMID:
19906266
16.

Efficacy assessment in paediatric studies.

Wang S, Laitinen-Parkkonen P.

Handb Exp Pharmacol. 2011;205:149-68. doi: 10.1007/978-3-642-20195-0_7.

PMID:
21882110
17.

Estimating treatment difference for binary responses in the presence of surrogate endpoints.

Banerjee B, Biswas A.

Stat Med. 2011 Jan 30;30(2):186-96. doi: 10.1002/sim.4089. Epub 2010 Oct 20.

PMID:
20963764
18.

How to deal with multiple endpoints in clinical trials.

Neuhäuser M.

Fundam Clin Pharmacol. 2006 Dec;20(6):515-23. Review.

PMID:
17109645
19.
20.

Prentice's approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints.

Alonso A, Molenberghs G, Burzykowski T, Renard D, Geys H, Shkedy Z, Tibaldi F, Abrahantes JC, Buyse M.

Biometrics. 2004 Sep;60(3):724-8.

PMID:
15339295

Supplemental Content

Support Center